利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.028 秒)

    LED module latch system
    1.
    发明授权
    LED module latch system 有权
    LED模块闩锁系统

    公开(公告)号：US06816389B1

    公开(公告)日：2004-11-09

    申请号：US10459952

    申请日：2003-06-12

    申请人： Robert J. Lutz ,  Neil J. Andal ,  Nathan L. Nearman

    发明人： Robert J. Lutz ,  Neil J. Andal ,  Nathan L. Nearman

    IPC分类号： H05K714

    CPC分类号： H05K5/0247

    摘要： An LED module latch system for quickly and readily attaching or detaching an LED module to an included mounting panel in an informational display. An LED module having one or more positionable helical spring latches adjacent to the geometry of the mounting panel is secured to the mounting panel by engagement of the helical spring latches. Each helical spring latch includes a pivot pin and a helical spring which are rotatingly positioned to cause intimate rotational engagement of the helical springs with the geometry of the mounting panel.

    摘要翻译： 一种LED模块闩锁系统，用于在信息显示中快速方便地将LED模块附接或拆卸到附带的安装面板。 具有与安装面板的几何形状相邻的一个或多个可定位的螺旋弹簧闩锁的LED模块通过螺旋弹簧闩锁的接合而固定到安装面板上。 每个螺旋弹簧闩锁包括旋转定位的枢轴销和螺旋弹簧，以使螺旋弹簧与安装面板的几何形状紧密地旋转接合。

    Method for pressure mediated selective delivery of therapeutic substances and cannula
    2.
    发明授权
    Method for pressure mediated selective delivery of therapeutic substances and cannula 失效
    压力介导选择性递送治疗物质和插管的方法

    公开(公告)号：US08409166B2

    公开(公告)日：2013-04-02

    申请号：US13094764

    申请日：2011-04-26

    申请人： Stephen M. Wiener ,  Robert F. Hoyt, Jr. ,  John R. Deleonardis ,  Randall R. Clevenger ,  Robert J. Lutz ,  Douglas V. Christini ,  Brian Safer

    发明人： Stephen M. Wiener ,  Robert F. Hoyt, Jr. ,  John R. Deleonardis ,  Randall R. Clevenger ,  Robert J. Lutz ,  Douglas V. Christini ,  Brian Safer

    IPC分类号： A61M31/00

    CPC分类号： A61M25/1011 ,  A61B17/3417 ,  A61B2017/3425 ,  A61M25/02 ,  A61M25/04 ,  A61M2025/0233

    摘要： Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity. Occlusion of venous or lymphatic drainage from the organ can also help prevent systemic administration of therapeutic substances, and increase selective delivery to superficial epithelial cellular layers. Delivery of genetic vectors can also be better targeted to cells where gene expression is desired. The access device comprises a cannula with a wall piercing tracar within the lumen. Two axially spaced inflatable balloons engage the wall securing the cannula and sealing the puncture site. A catheter equipped with an occlusion balloon is guided through the cannula to the location where the therapeutic substance is to be delivered.

    摘要翻译： 公开了用于将治疗物质选择性递送到器官的特定组织学或微解剖区域的方法和装置。 以受控的压力，体积或速率将治疗物质引入中空器官空间（例如肝胆管或胆囊腔）中允许物质到达预定的细胞层（例如上睑或上皮上皮空间）。 可以控制物质的体积或流速，使得腔内压力达到预定阈值水平，超过此阈值水平发生物质的后续上皮下递送。 或者，选择不超过阈值水平的较低压力，使得递送基本上仅发生在上皮层。 治疗剂的这种位点特异性递送允许以另外可能产生全身毒性的浓度局部递送物质（例如，器官的间质组织）。 从器官中静脉或淋巴引流的阻塞还可以帮助防止治疗物质的全身给药，并增加对表面上皮细胞层的选择性递送。 遗传载体的递送也可以更好地靶向需要基因表达的细胞。 进入装置包括在管腔内具有穿孔孔的套管。 两个轴向间隔开的可充气气囊与固定插管并密封穿刺部位的壁接合。 配备有闭塞气囊的导管通过套管被引导到治疗物质要被输送的位置。

    NOVEL SYNERGISTIC EFFECTS
    3.
    发明申请
    NOVEL SYNERGISTIC EFFECTS 失效
    新的协同效应

    公开(公告)号：US20100028346A1

    公开(公告)日：2010-02-04

    申请号：US12485446

    申请日：2009-06-16

    申请人： Robert J. Lutz ,  Kathleen R. Whiteman

    发明人： Robert J. Lutz ,  Kathleen R. Whiteman

    IPC分类号： A61K39/395 ,  A61K31/436 ,  A61K31/664 ,  A61P35/00 ,  A61P37/06 ,  A61P31/12 ,  A61P33/00 ,  A61K31/713 ,  A61K31/56

    CPC分类号： C07K16/2803 ,  A61K31/198 ,  A61K31/436 ,  A61K31/454 ,  A61K31/57 ,  A61K31/675 ,  A61K31/69 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/24 ,  A61K2300/00

    摘要： The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone or the administration of one or more of the drug(s) without the conjugate. The present invention is also directed to compositions comprising at least one conjugate and at one or more of chemotherapeutic agent and to methods of treating cancer using at least one conjugate and at least one or more of chemotherapeutic agent (s). The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of one or more chemotherapeutic agent(s) and at least one conjugate. In each case, such combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the anticancer agent(s) alone.

    摘要翻译： 本发明包括至少一种缀合物和一种或多种化学治疗剂的组合，其当施用时施加意想不到的增强的治疗效果。 组合的治疗效果大于单独的缀合物或施用一种或多种没有缀合物的药物。 本发明还涉及包含至少一种缀合物和一种或多种化学治疗剂的组合物和使用至少一种缀合物和至少一种或多种化学治疗剂治疗癌症的方法。 本发明还提供了通过施用治疗有效量的一种或多种化学治疗剂和至少一种缀合物来调节所选细胞群体如癌细胞的生长的方法。 在每种情况下，这种组合具有治疗性协同作用或改善治疗癌症的治疗指数超过单独的抗癌剂。

    Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same
    4.
    发明授权
    Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same 有权
    抗CD33抗体及其治疗急性骨髓性白血病的方法

    公开(公告)号：US08337855B2

    公开(公告)日：2012-12-25

    申请号：US13019478

    申请日：2011-02-02

    申请人： Mary G. Hoffee ,  Daniel Tavares ,  Robert J. Lutz

    发明人： Mary G. Hoffee ,  Daniel Tavares ,  Robert J. Lutz

    IPC分类号： A61K38/00 ,  C07K16/28

    CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/92

    摘要： The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.

    摘要翻译： 本发明涉及结合CD33的抗体。 更具体地说，本发明涉及抗CD33抗体，这些抗体的片段和同系物，这些抗体的人源化和表面改变的版本，这些抗体的功能等同物和改进形式，免疫偶联物和包含这些抗体的组合物，以及其在诊断中的用途 ，研究和治疗应用。 本发明还涉及编码这些抗体的多核苷酸，包含多核苷酸的载体，用多核苷酸转化的宿主细胞和产生这些抗体的方法。

    Outdoor electrical display sign with an electrical resistance heater
    7.
    发明授权
    Outdoor electrical display sign with an electrical resistance heater 失效
    户外电气显示符号带电阻加热器

    公开(公告)号：US06615521B1

    公开(公告)日：2003-09-09

    申请号：US09736510

    申请日：2000-12-13

    申请人： Robert J. Lutz

    发明人： Robert J. Lutz

    IPC分类号： G09E700

    CPC分类号： G09F9/30 ,  G09F7/00

    摘要： An outdoor electrical display sign with an electrical resistance heating element on a transparent front panel thereof for removing condensation or for dissipating precipitation from the surfaces of the transparent front panel of the sign. The electrical resistance heating element can be adhesively secured onto a surface of the transparent front panel, taped onto a surface of the transparent front panel, laminated between the transparent front panel and an additional transparent polymer panel, photoscreened onto a surface of the transparent front panel, photo-etched onto a surface of the transparent front panel, or formed by pouring electrical resistance material into minute grooves formed in the transparent front panel. The electrical resistance heating element can be on either the inner surface or the outer surface of the transparent front panel, preferably the inner surface.

    摘要翻译： 在透明的前面板上具有电阻加热元件的室外电子显示器标志，用于去除冷凝或从符号的透明前面板的表面散发沉淀物。 电阻加热元件可以粘合地固定在透明前面板的表面上，贴在透明前面板的表面上，层压在透明前面板和另外的透明聚合物面板之间，被筛网到透明前面板的表面上 ，光刻蚀到透明前面板的表面上，或者通过将电阻材料注入到形成在透明前面板中的微小凹槽中形成。 电阻加热元件可以在透明前面板的内表面或外表面上，优选内表面。

    Anti-integrin immunoconjugates, methods and uses
    8.
    发明授权
    Anti-integrin immunoconjugates, methods and uses 失效
    抗整联蛋白免疫缀合物，方法和用途

    公开(公告)号：US08603483B2

    公开(公告)日：2013-12-10

    申请号：US11290249

    申请日：2005-11-30

    申请人： Qiming Chen ,  Mohit Trikha ,  Robert J. Lutz ,  Rita M. Steeves ,  Godfrey Amphlett

    发明人： Qiming Chen ,  Mohit Trikha ,  Robert J. Lutz ,  Rita M. Steeves ,  Godfrey Amphlett

    IPC分类号： C07K16/00 ,  C07K17/06 ,  A61K39/44

    CPC分类号： A61K47/48569 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/21 ,  C07K2317/73

    摘要： The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

    摘要翻译： 本发明涉及抗整联蛋白特异性抗体与细胞毒性化合物的缀合物，用于癌症治疗或由细胞增殖，细胞迁移或炎症介导的其它疾病的这种缀合物的合成，选择和使用以及哪些病理学涉及血管生成或新生血管形成 的新组织。 此外，本发明涉及这些疾病的组合治疗，其中治疗包括使用所述缀合物与一种或多种其它治疗方式的组合，包括但不限于化疗，手术或放射治疗。 优选的缀合物含有通过二硫键与抗体连接的美登木素生物碱化合物，优选的化学治疗剂是多柔比星，紫杉烷，喜树碱，鬼臼毒素，核苷类似物或嘧啶类似物。

    Transistor level verilog
    10.
    发明授权
    Transistor level verilog 有权
    晶体管级Verilog

    公开(公告)号：US07587305B2

    公开(公告)日：2009-09-08

    申请号：US10180265

    申请日：2002-06-26

    申请人： Robert J. Lutz ,  Mark S. Birrittella ,  Eric C. Fromm ,  Harro Zimmermann

    发明人： Robert J. Lutz ,  Mark S. Birrittella ,  Eric C. Fromm ,  Harro Zimmermann

    IPC分类号： G06F17/50

    CPC分类号： G06F17/5022 ,  G06F17/5036

    摘要： A method includes specifying a first set of interconnected devices associated with a first leaf cell in Verilog syntax, and specifying a second set of interconnected devices associated with a second leaf cell in Verilog syntax. A connection between the first leaf cell and the second leaf cell is also specified in Verilog syntax. This specifies a circuit. The functionality of the logic can be tested by running a logic simulation on the circuit without converting to Verilog syntax. The Verilog syntax, associated with the circuit, can be converted directly from Verilog syntax to a SPICE netlist. The SPICE netlist can be used to simulate the timing and other parameters of the circuit. The Verilog syntax can be used to verify the circuit. Also included are a computer readable medium including an instruction set for the above method, and a data structure necessary to carry out the above method.

    摘要翻译： 一种方法包括在Verilog语法中指定与第一叶单元相关联的第一组互连设备，以及在Verilog语法中指定与第二叶单元相关联的第二组互连设备。 在Verilog语法中也指定了第一个叶单元和第二个叶单元之间的连接。 这指定一个电路。 可以通过在电路上运行逻辑仿真而不转换为Verilog语法来测试逻辑的功能。 与电路相关的Verilog语法可以直接从Verilog语法转换为SPICE网表。 SPICE网表可用于模拟电路的时序和其他参数。 Verilog语法可用于验证电路。 还包括包括用于上述方法的指令集的计算机可读介质，以及执行上述方法所需的数据结构。